Bcl-6 is a transcription factor that is normally expressed in germinal centre B cells. It is essential for the formation of germinal centres and the production of high-affinity antibodies. Transcriptional downregulation of Bcl-6 occurs on terminal differentiation to plasma cells. Bcl-6 is highly expressed in B-cell non-Hodgkin's lymphoma and, in a subset of cases of diffuse large cell lymphoma, the mechanism of Bcl-6 overexpression involves interruption of normal transcriptional controls. Transcriptional control of Bcl-6 is, therefore, important for normal antibody responses and lymphomagenesis, but little is known of the cis-acting control elements. This report focuses on a region of mouse/human sequence homology in the first intron of Bcl-6, which is a candidate site for such a control element. We demonstrate that poly-(ADP-ribose) polymerase-1 (Parp-1) binds in vitro and in vivo to specific sequences in this region. We further show that PARP inhibitors, and Parp-1 knockdown by siRNA induce Bcl-6 mRNA expression in Bcl-6 expressing cell lines. We speculate that Parp-1 activation plays a role in switching off Bcl-6 transcription and subsequent B-cell exit from the germinal centre.
Introduction
Bcl-6 is a transcriptional repressor (Chang et al., 1996) that is expressed at high level in germinal centre B cells (Cattoretti et al., 1995) and is essential for the formation and maintenance of these structures (Dent et al., 1997; Ye et al., 1997) . Bcl-6 is also expressed in several types of non-Hodgkin's lymphoma including follicular lymphoma, Burkitt's lymphoma, lymphocyte predominant Hodgkin's lymphoma and diffuse large B-cell lymphoma. Bcl-6 is involved in chromosomal translocations (often but not exclusively with the immunoglobulin heavy-chain locus) in 20-30% of diffuse large cell lymphomas (Offit et al., 1994; Ye et al., 1993 Ye et al., , 1995 . The effect of the translocations is to place the coding exons of Bcl-6 under the control of heterologous control sequences, and therefore, separate them from the normal cis-acting control regions.
Other mechanisms of lymphomagenesis, in addition to deregulation by chromosomal translocations, have implicated Bcl-6. There is a high-affinity Bcl-6-binding site in exon 1 of the Bcl-6 gene (Kikuchi et al., 2000; Pasqualucci et al., 2003) . Point mutations of this binding site are associated with overexpression of Bcl-6 in about 10% of cases of human diffuse large cell lymphoma (Wang et al., 2002) , and consistent with this, reporter assays show that in normal B cells it is an inhibitory transcriptional control region (Kikuchi et al., 2000; Pasqualucci et al., 2003) . For Bcl-6 transcription to be maintained within germinal centres there must be, as yet unknown, mechanisms to inhibit this negative autoregulatory pathway.
Bcl-6 has a C-terminal zinc finger domain responsible for binding to specific DNA sequence, an N-terminal poxvirus and zinc finger (POZ) domain and a central portion that contains PEST domains and acetylation sites (Niu et al., 1998; Bereschenko et al., 2002) that mediate regulation of the protein's stability. All three domains have been shown to associate with corepressors: the zinc finger domain associates with ETO (Chevallier et al., 2004) , the central portion with Mi-2/ NuRD (Fujita et al., 2004) and the POZ domain with corepressors silencing mediator for retinoid acid receptor and thyroid hormone receptor (SMRT) and nuclear receptor corepressor (NcoR) (Huynh and Bardwell, 1998) . SMRT and NCoR, in turn, recruit histone deacetylase to accomplish transcriptional repression (Chang et al., 1996) . Disruption of the association between the Bcl-6 POZ domain and SMRT is sufficient to lead to death of Bcl-6 expressing diffuse large cell lymphoma cell lines (Polo et al., 2004) . In a different approach, a peptide aptamer binding to the POZ domain and reducing Bcl-6 function can kill Burkitt'slymphoma cell lines, which also express Bcl-6 (Chattopadhyay et al., 2006). Bcl-6 is, therefore, a therapeutic target in lymphoma. Little is known of the transcriptional regulation of Bcl-6, but understanding this process may lead to new strategies for the treatment of lymphoma.
Regions of intronic sequence homology are probable sites of regulatory elements (Gottgens et al., 2001) . Genomic sequence comparisons reveal a segment of mouse/human homology in the first intron of Bcl-6 (Bernardin et al., 1997) , which is immediately upstream of chromosomal breakpoints in diffuse large cell lymphoma and occasional deletions in cell lines derived from patients with lymphoma.
We reasoned that this Bcl-6 intron 1 sequence contains elements that are important in regulating transcription, and in this report we characterize the region in detail. We identify poly-(ADP-ribose) polymerase-1 (Parp-1) as binding to this region and we demonstrate an effect of PARP inhibitors and ablation of Parp-1 on Bcl-6 transcription.
Results
Definition of a region of DNA sequence homology in intron 1 of Bcl-6 Putative transcriptional control regions are located in regions of intronic sequence homology between species (Gottgens et al., 2001) . We, therefore, compared the sequences of the Bcl-6 locus of man, dog and mouse (Chapman et al., 2004) . The longest stretch of homology is immediately downstream of exon 1 in intron 1 (Figure 1a ). BLAST search of this region shows that the region of mouse/human homology extends for 174-bp and starts 87 bp downstream of exon 1 (Figure 1b) .
Definition of protein-binding sites
To define possible protein-binding sites six overlapping oligonucleotides covering the 174-bp region of homology ( Figure 1b) were tested in gel shift assays. Whole cell lysates from the activation-induced deaminase expressing, Bcl-6 expressing Balb/c mouse lymphoma cell line, A20 (Ma et al., 2002) were incubated with radiolabelled oligonucleotides. Prominent protein-DNA complexes are seen with oligonucleotides-3, -4 and -5 (black arrowhead and asterisk in Figures 2a) . The upper protein-DNA complex (black arrowhead) is weakly present with oligonucleotide-6. The lower complex (marked by an asterisk) is also seen more weakly with oligonucleotides-1, -2 and -6. In addition, oligonucleotide-1 is associated with protein-DNA complexes not observed with the other oligonucleotides (grey arrowheads).
We focused further work on oligonucleotide-4, as this is the central sequence for which prominent protein-DNA complexes were seen.
Identification of Parp-1 binding and a Parp-1-binding site To define the protein complex bound to oligonucleotide-4, we allowed whole cell lysates from A20 cells to bind to biotinylated oligonucleotide-4 in the presence of excess poly(dI-dC) to compete non-specific DNA-binding proteins. The biotinylated DNA-protein complex was, in turn, bound to streptavidin-coated magnetic beads, which were washed and the bound proteins eluted. Wash and eluate fractions were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Although several proteins were detectable in an early eluate ( Figure 2b , lane 7), a protein complex of 120 kDa was the strongest in a later fraction (Figure 2b , lane 8).
To control for non-specific protein-binding to DNA, we repeated the experiment utilizing a biotinylated nonspecific competitor (NSC) oligonucleotide (Huang et al., 2004) (Figure 2c ) as well as oligonucleotide-2 (data not shown). In neither case was a 120 kDa protein complex eluted. To identify the constituents of the 120 kDa band, it was cut from the gel and subjected to mass spectrometry. Parp-1 was identified in 24 peptides with a highly significant probability score of 1045 and with coverage of 28% of the protein from amino-acid positions 35-903. Two peptides matching the sequence of nucleolin, a protein known to associate with Parp-1 in a complex that enhances class-switch recombination (Borggrefe et al., 1998) were also isolated, but no other peptides were identified more than once.
Gel shift assays using anti-Parp-1 antibody were used to confirm that the protein-DNA complexes observed (Figure 3a) . In the absence of antibody, the complexes observed previously (Figure 2a ) are seen (black arrowhead and asterisk). A total of 0.5 and 1 ml of anti-Parp-1 produce minor supershifted bands (grey arrowhead), and 5 ml of antibody produces a supershift (grey arrowhead) with reduction in intensity of the other bands (black arrowhead and asterisk).
To find out if Parp-1 bound DNA directly, we carried out gel shift assays utilizing recombinant Parp-1 and labelled oligonucleotide-4 that had been blocked with streptavidin ( Figure 3b ) to prevent non-specific binding to DNA ends. Binding of recombinant Parp-1 to endblocked oligonucleotide-4 produced a shift that was not observed with an end-blocked NSC oligonucleotide (Huang et al., 2004) .
Parp-1 can bind DNA in a sequence-specific manner. Various binding sequences have been described (Butler and Ordahl 1999; Cervellera and Sala 2000; Akiyama et al., 2001; Nirodi et al., 2001; Zhang et al., 2002; Huang et al., 2004) , and although there is a shared trinucleotide sequence between two of these sites (tgttg (Huang et al., 2004) and ttgannacaa (Zhang et al., 2002) ), there is no significant match between the other known Parp-1-binding sequences. We noticed that oligonucleotide-4 contains two sequences in tandem, separated by 12 bp, with homology to a previously identified Parp-1-binding site (Zhang et al., 2002) (Figure 3c ). Mutated oligonucleotides were used in gel Parp-1 and Bcl-6 transcription HE Ambrose et al shift assays to compete the binding of A20 cell lysate to labelled oligonucleotide-4 ( Figure 3d ). Cold oligonucleotide-4 competed effectively with labelled oligonucleotide-4 (compare lanes 2 and 3 with lane 1) to abolish both protein-DNA complexes (black arrowhead and asterisk). An oligonucleotide bearing mutations of the two putative-binding sites (M1) had reduced ability to compete (compare lanes 4 and 5 with lanes 2 and 3), whereas mutation of the intervening sequence (M2) did not impair competition (compare lanes 6 and 7 with lanes 2 and 3), thus supporting the view that Parp-1 directly binds DNA through these sequences. A cold competitor oligonucleotide with mutated upstreambinding site (M3) competes more effectively with labelled oligonucleotide-4 than M4, which has a mutated downstream site (compare lanes 8 and 9 with lanes 10 and 11). This suggests that the upstream site has a higher affinity than the downstream site for the protein complex that includes Parp-1, which is compatible with the fact that the sequence of this site (ttgatataaa) is more homologous to the Parp-1 binding sequence found by others (Zhang et al., 2002; ttgannagaa) than the downstream site. The competition (Figure 3d ) and supershift experiments (Figure 3a) show that both protein-DNA complexes (black arrowhead and asterisk) contain Parp-1. It is likely that the two complexes represent an association of Parp-1 with different proteins.
Oligonucleotides-3 and -5 bind protein-DNA complexes with the same mobility on gel shift assay as oligonucleotide-4 (Figure 2a) . However, oligonucleotides-3 and -5 only contain partial Parp-1-binding sites. It is possible that in the context of non-end-blocked oligonucleotides these sequences are sufficient to bind Parp-1. The human downstream Parp-1 binding sequence has a base change (G-T) from the mouse sequence that reduces homology to the consensus sequence.
In vivo binding of Bcl-6
To show that Parp-1 binds in vivo, we carried out chromatin immunoprecipitation (ChIP) (Figure 4a) . Fixed, sheared chromatin was immunoprecipitated with anti-Parp-1 antibody and the mouse/human homology sequence was polymerase chain reaction (PCR) amplified. As a negative control (NC) the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter (Polo et al., 2004) , which does not bind Parp-1, was used. Although both Bcl-6 intron sequence and GAPDH promoter sequence were present in the input material, only the anti-Parp-1 immunoprecipitated chromatincontained Bcl-6 intron 1 sequence. Parp-1 binds both in Bcl-6 expressing A20 cells and also in the mouse plasma cell line MPC11, which does not express Bcl-6. Semiquantitative real-time PCR demonstrated that the enrichment of target sequence with anti-Parp-1 antibody is approximately 10-fold (Figure 4b ).
Ablation of Parp-1 induces Bcl-6 expression
We utilized small interfering RNA (siRNA) to knock down Parp-1 in mouse and human cell lines (Figure 4c and d). To control for the effects of transfection and non-specific siRNA effects we also measured Bcl-6 expression in mock-transfected (MT) cells and those transfected with a negative control siRNA. The effect of knockdown was to induce Bcl-6 expression in mouse A20 and human Ramos cell lines, which both express Bcl-6, and no such increase was observed with MT or NC controls (Figure 4e) .
We also over-expressed Parp-1 by transfecting a Parp-1 expression plasmid into A20 cells, but we could not demonstrate a significant change in Bcl-6 expression (Supplementary Figure 1) possibly because Parp-1 is already highly expressed in these cells.
Inhibition of PARP activity induces Bcl-6 expression
We next sought to find out if inhibition of the catalytic activity of Parp-1 altered Bcl-6 transcription. A20 cells were cultured with the PARP inhibitors, 3-aminobenzamide Parp-1 and Bcl-6 transcription HE Ambrose et al (3-AB) and NU1025. Induction of Bcl-6 at early time points after addition of inhibitor was measured by realtime semi-quantitative PCR (Figure 5a) . A relative increase of Bcl-6 expression was observed after 2 h with both inhibitors. Induction of Bcl-6 was not specific for mouse cells but was also observed in the human Burkitt's lymphoma cell line, Ramos, which is also Bcl-6 expressing ( Figure 5c ). No induction of Bcl-6 was observed with the mouse, MPC11 or human, U266, plasma cell lines that do not express Bcl-6 (Figure 5b and d).
To attempt to control for genetic differences between cell lines we tested the effects of PARP inhibitors on human lymphoblastoid cell lines Mutu I and Mutu III. These are Epstein-Barr virus infected and derived from the same patient, but Mutu I expresses Bcl-6 and Mutu III does not express Bcl-6 (Gregory et al., 1990) . PARP inhibitors produced a relative increase in Bcl-6 expression in Mutu I but no increase in Mutu III (Figure 5e and f). Therefore, both PARP inhibitors and Parp-1 knockdown produce an induction of Bcl-6 expression.
Discussion
Expression of Bcl-6 is tightly developmentally regulated with high expression in germinal centre B cells and absent expression in both naı¨ve B cells and terminally differentiated plasma cells. Little is known of the transcriptional control of Bcl-6, but disruption of a negative autoregulatory Bcl-6-binding site in exon 1 has been implicated in some cases of diffuse large cell lymphoma (Wang et al., 2002; Pasqualucci et al., 2003) . Recently, a STAT-5 binding site located upstream of exon 1 has also been shown to inhibit Bcl-6 transcription, and mutation of this site has been proposed to contribute to lymphomagenesis (Walker et al., 2007) . Our data demonstrate sequence-specific binding of Parp-1 in the first intron of Bcl-6 and induction of Bcl-6 transcription both by PARP inhibitors and by knockdown of Parp-1 expression. Collectively, our results suggest a model in which Parp-1 activation and its physical presence have roles in regulating Bcl-6 transcription.
Parp-1 is the founder member of a 17 protein family of structurally related molecules (Ame et al., 2004; Schreiber et al., 2006) . There is an N-terminal DNA binding domain and a C-terminal b-nicotinamide adenine dinucleotide (NAD þ ) binding catalytic domain. The central section of Parp-1 contains an automodification domain, which also associates with other proteins (Masson et al., 1998) . Parp-1 has roles in DNA repair (Durkacz et al., 1980; Satoh and Lindahl 1992) , but more recently has been shown to regulate transcription (Kraus and Lis 2003; Pirrotta 2003) .
Parp-1 has been reported to both repress and induce transcription of target genes (D'Amours et al., 1999; Kraus and Lis, 2003) by several different mechanisms. First, Parp-1 is a constituent of chromatin and Parp-1 activity mediates chromatin relaxation (Poirier et al., 1982; Kim et al., 2004; Rouleau et al., 2004) thereby altering accessibility to transcription factors. Diverse mechanisms for nucleosome-specific recruitment are beginning to be defined. For example, Parp-1 is bound to the histone variant mH2A1.1 and inactivated at mammalian heat-shock promoter Hsp70.1 (Ouararhni et al., 2006) . Heat shock causes release of Parp-1, enzymatic activation and relaxation of chromatin. At other promoters Parp-1 is recruited to nucleosomes with topoisomeraseIIb and DNA-dependent protein kinase (DNA-PK) (Ju et al., 2006) . Here activation of Parp-1 by topoisomeraseIIb-induced DNA strand breaks induces gene transcription.
Parp-1 is a component of some transcription factor complexes (Akiyama et al., 2001; Simbulan-Rosenthal et al., 2003; Ju et al., 2004; Pavri et al., 2005) and can regulate transcription by modifying the activity of enhancer and promoter elements. It can contact DNA directly either by specific sequence recognition (Zhang et al., 2002; Huang et al., 2004; Amiri et al., 2006) or possibly by binding to secondary hairpin structures (Lonskaya et al., 2005; Potaman et al., 2005) . In some transcription factor complexes, Parp-1 has a coactivator role and associates with other proteins in a manner that Reduction in PARP activity produces an increase in Bcl-6 transcription. Real-time semi-quantitative PCR was used to measure Bcl-6 mRNA at 0, 2 and 4 h. The values plotted are normalized for the amount of HPRT mRNA. The data points represent the mean values of three experiments7s.e.m. Concentrations of 3-aminobenzamide are in mM, and of NU1025 in mM. PARP inhibitors induce Bcl-6 expression in (a) A20 cells, but not in (b) the mouse plasma cell line MPC11, which does not express Bcl-6. Similar effects were seen with (c) the human Bcl-6 expressing Burkitt's lymphoma cell line, Ramos, but not with (d) the human plasma cell line U266. PARP inhibitors induce Bcl-6 transcription in (e) Bcl-6 expressing Mutu I but not (f) Bcl-6 negative Mutu III. Mutu I and Mutu III are human B-cell lines that are derived from the same lymphoma but differ in Bcl-6 expression.
Parp-1 and Bcl-6 transcription HE Ambrose et al is not dependent on its catalytic or DNA-binding properties (Hassa et al., 2001; Simbulan-Rosenthal et al., 2003; Pavri et al., 2005) . Our results suggest that catalytic activity of Parp-1 is important at the Bcl-6 locus, and therefore, a coactivator role (Hassa et al., 2001 ) is not likely. Others have demonstrated a dual effect at some promoters whereby Parp-1 inhibition represses expression and Parp-1 knockdown has the opposite effect (Amiri et al., 2006; Soldatenkov et al., 2002) . The proposed mechanism for this is that Parp-1 binding represses transcription but activation of Parp-1 followed by auto poly-(ADP-ribosylation) and dissociation from DNA leads to induction of transcription. Our findings that both PARP inhibition, and knockdown induce Bcl-6 expression argue that this mechanism does not operate at the Bcl-6 locus.
Experimentally transcriptional control regions are often defined by reporter assays. A survey of the first exon and first intron of Bcl-6 has shown (Kikuchi et al., 2000) that the region investigated in this report does not activate or repress transcription in luciferase reporter assays. An explanation for the luciferase reporter assay results is that Parp-1 exerts its effects at the Bcl-6 locus only when chromatin is in a natural conformation.
Our results show that inhibiting PARP activity or Parp-1 knockdown is associated with induction of Bcl-6 transcription and conversely we infer that increased PARP activity at this locus will cause a decrease in Bcl-6 transcription. We speculate that locally increased Parp-1 activation at the Bcl-6 locus causes chromatin relaxation. There are two well-characterized mechanisms for inhibiting Bcl-6 transcription close to the Parp-1-binding sites we report. These are Bcl-6 binding to exon 1 (Wang et al., 2002; Pasqualucci et al., 2003) and STAT-5 binding just upstream of this (Walker et al., 2007) . We speculate that local Parp-1 activation and consequent chromatin relaxation causes increased accessibility to Bcl-6 and STAT-5 whose effect is to reduce Bcl-6 transcription.
This model predicts that a substantial reduction in the amount of Parp-1 would have the same effect as inhibition of enzyme activity and it is, therefore, compatible with our results.
Parp-1 and -2 are the only members of this gene family known to be activated by DNA strand breaks (Huber et al., 2004) and it has been suggested that such breaks could have a role in activating Parp-1 and induction of target gene transcription (Pirrotta 2003; Haince et al., 2006; Ju et al., 2006) . Somatic hypermutation of antibody genes is essential to germinalcentre function and involves the introduction of point mutations into the sequence of antibody genes to produce high-affinity antibodies. The mechanism of somatic hypermutation generates and resolves DNA strand breaks (Sale and Neuberger 1998; Bross et al., 2000) and potentially provides a local means for activating Parp-1.
The region on which we focus is a site where multiple signals are integrated to control Bcl-6 expression. The Parp-1-binding sites we report are flanked by upstream inhibitory Bcl-6 and STAT-5-binding sites (Wang et al., 2002; Pasqualucci et al., 2003; Walker et al., 2007) and a downstream p53-binding site (Margalit et al., 2006) . Our work demonstrates that Parp-1 also has roles in this complex regulatory network.
Materials and methods

Cell lines
Mouse B-cell lymphoma cell line, A20, and human Burkitt's lymphoma cell line, Ramos, were maintained in RPMI 1640 (BioWhittaker Inc., Walkersville, MD, USA) and 10% fetal calf serum (PAA Laboratories GmbH, Pasching, Austria) with 50 mM b-mercaptoethanol.
Antibodies PARP was detected using rabbit anti-PARP antibody (Cell Signalling Technology, Danvers, MA, USA) at a dilution of 1:1000.
Electromobility shift assays Nuclear proteins were extracted (Schreiber et al., 1989 ) from 20 to 60 million cells. Cells were washed in HB buffer (10 mM Tris pH 7.4, 10 mM KCl, 1.5 mM MgCl and 0.5 mM bmercaptoethanol) and then lysed in HB buffer with 0.4% NP40. The extracted proteins were then re-suspended in buffer C (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.9, 0.4 M NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT) and 20% glycerol). Protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA) was added to all buffers. Each binding assay mixture (10 ml) contained 0.05 pmol of the 32 P-labelled probe in 5 mM MgCl 2 , 50 mM Tris-HCl, 2.5 mM EDTA, 2.5 mM DTT, 20% glycerol and 250 mM NaCl with 2 mg of poly(dI-dC) (Sigma). Cell lysate and radiolabelled probe were incubated at room temperature (RT) for 20 min. For the competition and supershift experiments all reactions were incubated for 15 min at RT before incubating with the radiolabelled probe for a further 20 min. For competition assays unlabelled competitor oligonucleotide was added at 1 and 5 pmol. Sequences of oligonucleotides are indicated in Figure 1 . NSC is 5 0 cagatacggtgaagatacgacca (Huang et al., 2004) . The reactions were separated on a 4% native polyacrylamide gel in 1 Â Tris-borate-EDTA (TBE) buffer for approximately 90 min at 200 V, dried under vacuum and autoradiographed with an intensifying screen at À701C.
Electrophoretic gel mobility shift assays using end-blocked probes were performed as follows. Oligonucleotides were biotinylated at the 5 0 end. The reverse sense oligonucleotide were 2 or 3 bases shorter than the sense strand to facilitate radiolabelling with Klenow polymerase (New England Biolabs, Ipswich, MA, USA). The complementary oligonucleotides were hybridized. The probe was labelled with [ 32 P]dCTP with Klenow polymerase and purified by G50 spin column. For binding assays, 90 fmol of labelled probe was preincubated with 50 pmol of streptavidin (Sigma) at RT for 5 min to block the DNA ends. The streptavidinylated probes were incubated with an excess poly(dI:dC) (10 mg) in DNAbinding buffer (Promega, Madison, MA, USA). In total, 70 pmol of rPARP-1 (Trevigen, Gaithersburg, MD, USA) was incubated with the 32 P-labeled DNA probe (100 000 c.p.m.) in a final volume of 20 ml for 15 min at RT. The protein-DNA complexes were then analysed by electrophoresis on a 5% native polyacrylamide gel in TBE buffer for approximately 15 min at 75 V and then for 150 min at 150 V, followed by autoradiography.
Immunomagnetic bead isolation of DNA binding Following the manufacturer's protocol (Miltenyi Biotec, Bergisch-Gladbach, Germany), A20 nuclear lysates were prepared and mixed with biotinylated oligo4 and mMACS streptavidin microbeads. The mixture was then applied to a micro column in the magnetic field of a mMACS separator. The bound nuclear proteins were washed and then eluted with a high-salt buffer (1 M NaCl) according to the manufacturer's instructions. Fractions were run on a 7.5% acrylamide gel and visualized by the SilverQuest Silver Staining Kit (Invitrogen, Paisley, UK). MS/MS mass spectrometry QTOF II micromass instrument (MRC Clinical Sciences Centre, Proteomics Unit) was used to characterize any discrete protein bands identified in the wash fractions. The MASCOT search engine (www. matrixscience.com) was used for analysis.
Real-time semi-quantitative PCR Probe and primer sets for mouse Bcl-6 (Mm00477633_m1) and HPRT (Mm00446968_m1), and human Bcl-6 (Hs00277037_m1) and human HPRT (Hs99999909_m1) were purchased from Applied Biosystems (Warrington, UK). PCR was carried out in an ABI Prism 7700 Sequence Detector (Applied Biosystems) with reaction conditions 951C for 1 min, 501C for 15 s and 601C for 1 min for 40 cycles.
Chromatin immunoprecipitation
A total of 10 Â 10 6 A20 cells were fixed and lysed in a volume of 200 ml with ChIP lysis buffer (Upstate Biotechnology, Charlottesville, VA, USA). Following shearing of DNA by ultrasonication 7 Â 20 s (amplitude 4 m) and pre-clearing with protein A agarose, immunoprecipitation was carried out with 20 ml rabbit anti-PARP-1 (gift from Dr M Hottiger, Zurich) or normal rabbit IgG. Further processing was carried out as per manufacturer's instructions (Upstate Biotechnology). To PCR amplify the region of interest in intron 1 of Bcl-6, the following primers were used. Forward: 5 0 ctccaaaaccgaaacaacaccg, reverse: 5 0 ctctgttgattcttagaactggg. To amplify the mouse glyceraldehyde-3-phosphate dehydrogenase promoter, we used 5 0 catggactgtggtcatgag and 3 0 tgggaagcttgtcatcaacg. PCR conditions were 30 cycles of denaturation 951C for 1 min, annealing 601C for 1 min and extension 721C for 1 min. To carry out quantitative ChIP, chromatin was purified as above and analysed by real-time semi-quantitative PCR. Primers were designed using Primer Express (Applied Biosystems). Forward: gctttggctccaagtttcctat, probe: FAMtattgatataaatg tatctatttattgattctaTAMRA and reverse: cggcatttattttaacacct gaca. A standard curve was constructed from known dilutions of input chromatin. PCR conditions were as above.
siRNA against Parp-1 siRNA oligonucleotides directed against mouse and human Parp-1 were purchased from Ambion Inc. (Austin, TX, USA). #162163 and #111005 were the most effective against mouse Parp-1 and human Parp-1, respectively. Oligonucleotides (100 nM) were transfected by Nucleofector (Amaxa Biosystems, GmbH, Cologne, Germany) using program LO13. A NC oligonucleotide was also purchased from Ambion and used identically to the test oligonucleotides. Cells were harvested and RNA was produced 48 h after transfection (at the nadir of Parp-1 expression).
